Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the progression-free survival (PFS) of the combination of pembrolizumab and epacadostat versus pembrolizumab and placebo (i.e. 2 treatment groups) based on RECIST 1.1 by independent central review; and To compare overall survival (OS) of the 2 treatment groups.
Critère d'inclusion
- Melanoma